Treatment of schizophrenia negative symptoms: future prospects
- PMID: 16492797
- PMCID: PMC2632230
- DOI: 10.1093/schbul/sbj055
Treatment of schizophrenia negative symptoms: future prospects
Abstract
New findings from neuroscience, genetics, and experimental psychology have emerged that provide alternative explanations of many negative symptoms. We review the continuing limitations in treatment and discuss possible sources of heterogeneity among negative symptoms. We also anticipate conceptual uncertainties that may arise with forthcoming treatment developments.
Similar articles
-
Schizophrenia: D4 receptor elevation. What does it mean?J Psychiatry Neurosci. 1994 May;19(3):171-6. J Psychiatry Neurosci. 1994. PMID: 7913338 Free PMC article. Review. No abstract available.
-
Frontal lobe tasks, antipsychotic medication, and schizophrenia syndromes.Biol Psychiatry. 1996 Feb 1;39(3):227-9. doi: 10.1016/0006-3223(95)00387-8. Biol Psychiatry. 1996. PMID: 8837987 No abstract available.
-
New antipsychotic agents and the future.J Clin Psychiatry. 1985 Apr;46(4 Pt 2):51-3. J Clin Psychiatry. 1985. PMID: 2858482
-
Dopamine receptors and schizophrenia.Biochem Soc Trans. 1996 Feb;24(1):202-5. Biochem Soc Trans. 1996. PMID: 8674664 Review. No abstract available.
-
[Pathophysiology of schizophrenia and its impact on pharmacotherapy].Fortschr Neurol Psychiatr. 2005 Nov;73 Suppl 1:S32-7. doi: 10.1055/s-2005-915546. Fortschr Neurol Psychiatr. 2005. PMID: 16270242 Review. German.
Cited by
-
Facial and Vocal Markers of Schizophrenia Measured Using Remote Smartphone Assessments: Observational Study.JMIR Form Res. 2022 Jan 21;6(1):e26276. doi: 10.2196/26276. JMIR Form Res. 2022. PMID: 35060906 Free PMC article.
-
Somatic symptoms in schizophrenia: Association with socio-demographic and clinical characteristics, disability and quality of life.Indian J Psychiatry. 2023 Jul;65(7):749-754. doi: 10.4103/indianjpsychiatry.indianjpsychiatry_571_22. Epub 2023 Jul 12. Indian J Psychiatry. 2023. PMID: 37645357 Free PMC article.
-
Olfactory processing, sex effects and heterogeneity in schizophrenia.Schizophr Res. 2012 Mar;135(1-3):144-51. doi: 10.1016/j.schres.2011.11.025. Epub 2011 Dec 15. Schizophr Res. 2012. PMID: 22177347 Free PMC article.
-
Negative symptoms in youths with psychosis spectrum features: complementary scales in relation to neurocognitive performance and function.Schizophr Res. 2015 Aug;166(1-3):322-7. doi: 10.1016/j.schres.2015.05.037. Epub 2015 Jun 17. Schizophr Res. 2015. PMID: 26093946 Free PMC article.
-
Anhedonia in schizophrenia.Curr Psychiatry Rep. 2006 Aug;8(4):322-8. doi: 10.1007/s11920-006-0069-0. Curr Psychiatry Rep. 2006. PMID: 16879797 Review.
References
-
- Fleischhacker WW. New drugs for the treatment of schizophrenic patients. Acta Psychiatr Scand Suppl. 1995;388:24–30. - PubMed
-
- Lauriello J, Lenroot R, Bustillo J. Maximizing the synergy between pharmacotherapy and psychosocial therapies for schizophrenia. Psychiatr Clin North Am. 2003 Mar;26(1):191–211. - PubMed
-
- Kopelowicz A, Liberman R, Mintz J, Zarate R. Comparison of efficacy of social skills training for deficit and nondeficit negative symptoms in schizophrenia. Am J Psychiatry. 1997;154(3):424–425. - PubMed
-
- Leucht S, Pitschel-Walz G, Abraham D, Kissling W. Efficacy and extrapyramidal side effects of the new antipsychotics olanzapine, quetiapine, risperidone and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophr Res. 1999;35:51–68. - PubMed
-
- Tollefson G, Bealey C, Tran P, Street J, et al. Olanzapine versus Haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry. 1997;154:457–474. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical